Bellerophon presents new data from cohort 1 of ongoing phase 2/3 study of inopulse

Bellerophon presents new data from cohort 1 of ongoing phase 2/3 study of inopulse® for treatment of pulmonary hypertension associated with interstitial lung disease at pulmonary fibrosis foundation summit 2019.bellerophon therapeutics inc - inopulse demonstrated a consistent and clinically meaningful benefit in moderate to vigorous physical activity.
BLPH Ratings Summary
BLPH Quant Ranking